REGULATORY FRAMEWORK FOR ANONYMIZED MEDICAL DATA IN BIOTECHNOLOGY RESEARCH IN JAPAN

1. INTRODUCTION

Japan has developed a comprehensive legal framework governing the anonymization, processing, sharing and research use of medical information for biotechnology and healthcare innovation. The principal objective is to balance scientific advancement with patient privacy, confidentiality, data security and individual autonomy.

Anonymized medical information is particularly valuable for pharmaceutical development, genomic research, precision medicine, epidemiological studies, artificial intelligence-assisted diagnosis, clinical outcome analysis and development of regenerative medicine.

The principal legislation is the Act on the Protection of Personal Information (APPI) and the Act on Anonymously Processed Medical Information and Pseudonymously Processed Medical Information for the Contribution to Medical Research and Development, commonly known as the Next Generation Medical Infrastructure Act.

The latter legislation was amended and the new framework became effective on 1 April 2024, introducing pseudonymously processed medical information alongside the existing anonymized medical information system.

2. LEGAL FRAMEWORK GOVERNING MEDICAL DATA

A. ACT ON THE PROTECTION OF PERSONAL INFORMATION (APPI)

The APPI establishes the general framework for collecting, processing, storing and transferring personal information in Japan. Medical records, genetic information, diagnostic results and treatment histories generally require particularly careful protection because they can reveal sensitive information about individuals.

The APPI regulates:

Purpose specification and appropriate use of personal information.

Restrictions on use beyond the stated purpose.

Appropriate acquisition of personal information.

Security-control measures against unauthorized access and disclosure.

Restrictions on third-party provision of personal data.

Procedures for handling complaints and responding to data breaches.

Special requirements governing anonymously processed information.

Articles 43–46 establish important requirements for anonymously processed information, while Articles 37–38 address its provision and restrictions on identification.

B. NEXT GENERATION MEDICAL INFRASTRUCTURE ACT

This legislation provides a specialized mechanism for using medical information in research and development.

Its principal objectives include:

Facilitating medical and pharmaceutical innovation.

Supporting development of new medicines and treatment technologies.

Enabling large-scale analysis of medical information.

Protecting patients through regulated anonymization.

Establishing government-certified medical information processing organizations.

The framework permits qualifying medical information to be processed and made available for legitimate medical research and development.

3. ANONYMIZATION REQUIREMENTS

Medical information must undergo appropriate processing before it qualifies as anonymously processed information.

Important requirements include:

Removal of names, addresses and other direct identifiers.

Removal or transformation of identification codes.

Processing of dates and other identifying attributes where necessary.

Reduction of re-identification risks arising from rare diseases and unusual medical histories.

Prevention of identification through combinations with external datasets.

Appropriate technical and organizational security controls.

Simply deleting a patient's name does not automatically constitute legally sufficient anonymization.

Researchers must consider whether a person could reasonably be identified through combinations of genomic information, age, geographical information, rare diagnoses or other available datasets.

4. REQUIREMENTS FOR BIOTECHNOLOGY RESEARCH

Biotechnology organizations using anonymized medical information should ensure that:

The proposed research genuinely relates to medical research and development.

Data have been obtained through legally compliant channels.

The processing method satisfies applicable statutory standards.

Access is restricted to authorized research personnel.

Research datasets are protected against unauthorized disclosure.

Data are not combined with other information for prohibited identification.

Research purposes and data-use conditions are documented.

Any contractual restrictions imposed by data providers are followed.

Relevant research areas include genomic medicine, drug discovery, biomarker identification, cancer research, clinical analytics and development of personalized therapies.

5. PSEUDONYMIZED MEDICAL INFORMATION AFTER THE 2024 REFORM

The 2024 amendments introduced pseudonymously processed medical information to address the limitations of conventional anonymization.

Anonymization can require deleting or modifying information that is scientifically valuable, particularly information concerning rare diseases and unusual clinical characteristics.

Pseudonymization allows certain identifying information to be removed while retaining more detailed medical information for controlled research.

However, pseudonymized information is not equivalent to fully anonymized information.

Its utilization is restricted to appropriately certified organizations and authorized users. The framework imposes restrictions on identification, unauthorized disclosure and use beyond permitted purposes.

Consequently, biotechnology companies requiring longitudinal patient information or detailed rare-disease datasets must distinguish between the two legal categories before designing their research projects.

6. ROLE OF GOVERNMENT-CERTIFIED ORGANIZATIONS

The Next Generation Medical Infrastructure Act requires designated organizations involved in the creation and management of qualifying medical datasets to satisfy government certification requirements.

Their responsibilities include:

Collecting medical information through legally compliant procedures.

Processing information according to statutory anonymization standards.

Maintaining secure databases and access controls.

Preventing unauthorized re-identification.

Ensuring appropriate data disclosure and research-use arrangements.

Maintaining accountability and regulatory compliance.

Both universities and private biotechnology companies may benefit from the system, subject to the applicable requirements for each information category.

7. RELEVANT JAPANESE CASE LAWS

There is an important qualification: Japan has no established Supreme Court judgment specifically determining the legality of using Next Generation Medical Infrastructure Act anonymized datasets for biotechnology research. The following decisions are relevant privacy and constitutional authorities, rather than direct interpretations of that legislation.

A. DIRECTLY RELEVANT PRIVACY AUTHORITY

1. Waseda University Personal Information Disclosure Case (Supreme Court, 12 September 2003, Minshu 57(8), 973).

The Supreme Court held that personal information collected by a university could receive legal protection even when it consisted of relatively ordinary identifying details. Disclosure to police without consent, where consent could reasonably have been obtained, constituted a privacy infringement.

Relevance: Medical institutions and research organizations must respect reasonable expectations concerning the management and disclosure of patient information.

B. ANALOGOUS PRIVACY AUTHORITIES

2. Kyoto Prefectural Gakuren Case (Supreme Court Grand Bench, 24 December 1969, Keishu 23(12), 1625).

The Court recognized the individual's interest in not having their appearance photographed arbitrarily without justification, while accepting limited exceptions in the circumstances of the case.

Relevance: Supports privacy-sensitive approaches to collecting and processing information about individuals.

3. Shimon Ounatsu Fingerprinting Case (Supreme Court, 15 December 1995, Keishu 49(10), 842).

The Court considered the constitutional protection against compulsory fingerprinting without proper legal authorization.

Relevance: Provides an analogous basis for evaluating intrusive collection and processing of sensitive identifying information.

4. Juki Net Resident Registry Case (Supreme Court, 6 March 2008, Minshu 62(3), 665).

The Court examined the constitutional implications of a nationwide resident-registration information network. It rejected the constitutional challenge in the circumstances, considering the nature of the information and safeguards against misuse.

Relevance: Demonstrates that the legality of information systems depends on the nature of collected information, system design and protective safeguards.

5. After the Banquet Case (Tokyo District Court, 28 September 1964).

The Court recognized legal protection for private-life information in a dispute concerning the unauthorized use of personal details in a novel.

Relevance: Illustrates the importance of protecting private information against unauthorized use, including when information is reused for purposes different from its original context.

6. GPS Investigation Case (Supreme Court Grand Bench, 15 March 2017, Keishu 71(3), 13).

The Court held that secret GPS monitoring could intrude into an individual's private sphere and required judicial authorization under the applicable criminal-procedure framework.

Relevance: Provides an important analogy concerning continuous data collection, surveillance risks and the protection of private information.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Biotechnology companies and research institutions should:

Verify whether datasets qualify as anonymously or pseudonymously processed medical information.

Use certified processing channels where the Next Generation Medical Infrastructure Act applies.

Maintain documented data provenance and processing records.

Assess re-identification risks, especially for genomic and rare-disease datasets.

Restrict access through role-based authorization.

Conduct periodic privacy and cybersecurity assessments.

Establish contractual controls for research collaborators.

Prevent unauthorized linkage with external identification databases.

Establish incident-response and data-breach procedures.

9. CONCLUSION

Japan's regulatory framework promotes biotechnology innovation while protecting the confidentiality and privacy of medical information. The APPI provides the general data-protection foundation, while the Next Generation Medical Infrastructure Act establishes a specialized mechanism for anonymized and pseudonymized medical information used in research and development.

The 2024 reforms are particularly significant because they allow greater scientific utility through controlled pseudonymized medical datasets. Nevertheless, anonymization does not eliminate every legal obligation, and researchers must comply with applicable processing standards, access restrictions and re-identification prohibitions.

For biotechnology organizations, legal compliance requires balancing scientific utility, patient privacy, institutional accountability and cybersecurity. The Japanese framework therefore provides an important model for responsible medical-data governance and research innovation.